Sionna Therapeutics, Inc. SION · Stock Open Sionna Therapeutics, Inc. in new tab
Sionna Therapeutics, Inc. Analysis (SION)
Is Sionna Therapeutics, Inc. a good investment? Sionna Therapeutics, Inc. (SION) is currently trading at 5.91 USD. Market analysts have a consensus price target of 17.20 USD. This suggests a potential upside from current levels.
Earnings Schedule: Sionna Therapeutics, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -2.53.
Investor FAQ
Does Sionna Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -2.15.
Company Profile
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Community Discussion